Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011 (2011), Article ID 354760, 8 pages
http://dx.doi.org/10.4061/2011/354760
Clinical Study

Sleep Duration and “on” Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release

1Department of Neurology, University of Technology Dresden, Fetscherstraße 74, 01307 Dresden, Germany
2Neurosciences Center of Excellence, GlaxoSmithKline, Brentford, London TW8 9GS, UK
3Neurosciences Medicines Development Center, GlaxoSmithKline, Uxbridge, London UB11 1BT, UK
4Area of Applied Epidemiology, National Centre for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid 28029, Spain

Received 6 December 2010; Revised 28 February 2011; Accepted 6 March 2011

Academic Editor: Peter Hagell

Copyright © 2011 Heinz Reichmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Patients undergoing long-term therapy for PD often experience motor fluctuations and nocturnal disturbances. In a post-hoc analysis, we explored effects of ropinirole prolonged release on sleep, night-time awakenings, and “on” time over 24 hours. Patients with advanced PD suboptimally controlled with L-dopa were randomized to adjunctive ropinirole prolonged release (2–24 mg/day) or placebo for 24 weeks. Awake/asleep and, if awake, “on”/“off” status was recorded via diary cards. At week 24 last observation carried forward, changes in nighttime or daytime sleep duration were not significantly different between treatments. Of patients with baseline awakenings, a significantly higher proportion in the ropinirole prolonged release group had a reduction in awakenings versus placebo. Patients receiving ropinirole prolonged release had a significantly greater increase in amount/percentage of awake time “on”/“on” without troublesome dyskinesia during all periods assessed (including night-time and early morning), versus placebo, and higher odds for being “on” on waking. Adjunctive once-daily ropinirole prolonged release may help provide 24-hour symptom control in patients with advanced PD not optimally controlled with L-dopa.